Task Force Issues Detailed Proposal for Improving FDA Transparency

The FDA should disclose whenever an NDA, ANDA or BLA is submitted or withdrawn by a drugmaker, as well as detailed information about the company and the proposed product. The proposal, along with 20 others, was made Wednesday by the agency’s Transparency Task Force as the second phase of its transparency initiative, designed to shed light on the FDA’s operations and decisionmaking. The agency is seeking comments on the task force report by July 19.
Drug Industry Daily